As the Diageo share price falls another 6% in 2025, what should investors do?

The rise of GLP-1 drugs is sending the Diageo share price lower. But Stephen Wright thinks investors should try to avoid getting swept along by the fear.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young Asian woman with head in hands at her desk

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

The Diageo (LSE:DGE) share price just keeps going lower at the moment. It’s as if someone has told it the story of Jules Verne’s Journey to the Centre of the Earth and the stock thought “sounds like a plan…”.

Created with Highcharts 11.4.3Diageo Plc PriceZoom1M3M6MYTD1Y5Y10YALL14 Jan 202014 Jan 2025Zoom ▾Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '2520212021202220222023202320242024www.fool.co.uk

One of the biggest concerns is Glucagon-like Peptide-1 (GLP-1) drugs that help reverse the effects of diabetes and help combat obesity. And unlike a number of purported innovations – they actually work. 

It turns out though, that GLP-1 drugs aren’t just good for helping people lose weight. They’re also doing a decent job of knocking pounds off the FTSE 100 drinks company’s market cap

Should you invest £1,000 in Diageo right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Diageo made the list?

See the 6 stocks

As a result, Terry Smith has been selling his stake in Diageo, citing concerns about the impact of GLP-1 drugs on the drinks industry as a whole. But is this all just a big overreaction?

How big is the problem?

Gauging the scale of the threat precisely is impossible, but investors can give themselves a rough idea. In 2024, Diageo generated 30% of its sales from the US, where the obesity rate is around 40%. 

GLP-1 drugs are expensive and it looks as though only 50% of the people that might be eligible for them will be able to access them. And there’s a further unknown about how many will stick with it.

The effects wear off if the drugs aren’t taken every day. And with potential side-effects including nausea, sickness, and dizziness, there might well be some who find it difficult to keep taking them.

Lastly, there’s an important issue of demographics. While Diageo doesn’t publish demographic data explicitly, market studies indicate that around two-thirds of its customers are male.

That matters because around men only account for around a third of the people currently using GLP-1 drugs for weight loss. Given all this, I think rumours of this company’s demise are greatly exaggerated.

Risks and uncertainties

Based on these numbers, the impact on Diageo’s top line might be fairly limited. In a pretty optimistic scenario, the impact on revenues could be as low as 1.2% – or 4% of US sales. 

There’s a lot behind these numbers for investors to think about. For example, the firm typically earns strong margins in the US so a 1.2% hit to sales might translate into a bigger reduction in profits.

Another issue is whether people on GLP-1s are those who spend more on Diageo’s products. If they do, then losing that part of the customer base might result in a disproportionate reduction in revenues.

All this is to say that no investor should be dismissing the risk of weight-loss drugs entirely when it comes to Diageo shares. And they should absolutely not be counting on the above numbers as accurate.

I think a precise picture of the threat is impossible to construct at the moment. But I don’t think this justifies the sell-off in the stock, which is why I’m still looking to buy Diageo shares right now.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stephen Wright has positions in Diageo Plc. The Motley Fool UK has recommended Diageo Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Pound coins for sale — 51 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

This FTSE 250 trust is easily beating the global index in 2025. Time to buy?

One global FTSE 250 investment trust has been turning things round recently, with a handy bit of outperformance. Ben McPoland…

Read more »

Bournemouth at night with a fireworks display from the pier
Investing Articles

Is the fizz about to go from the Coca-Cola HBC share price?

The world’s most popular drink’s hitting the headlines again. Our writer considers whether there are any implications for the Coca-Cola…

Read more »

Portrait of a boy with the map of the world painted on his face.
Investing Articles

3 top FTSE 250 investment trusts to consider buying today 

This trio of high-quality trusts from the FTSE 250 index would give a Stocks and Shares ISA portfolio a truly…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Another strong set of results from this FTSE 100 telecoms company. Time to buy?

The FTSE 100’s Airtel Africa released its first-quarter earnings yesterday (24 July). Our writer’s been taking a closer look at…

Read more »

A quiet morning and an empty Victoria Street in Edinburgh's historic Old Town.
Investing Articles

The Rightmove share price is too hot… a pullback could be coming

The Rightmove share price has pushed above the consensus share price target. And while analysts are often wrong, this could…

Read more »

Branch of NatWest bank
Investing Articles

With the bank’s income, margin and earnings higher, the NatWest share price continues where it left off!

Post-pandemic the NatWest share price has been the third-best performer on the FTSE 100. Our writer looks at the bank’s…

Read more »

piggy bank, searching with binoculars
Growth Shares

Up 13% in a day, this FTSE 250 stock may be primed to rocket even higher

Jon Smith reviews a FTSE 250 company that's suddenly on everyone's minds, and outlines why the party's just getting started.

Read more »

Engineer Project Manager Talks With Scientist working on Computer
Investing Articles

After falling 16% in a day, this stock’s on my list of shares to buy in August

Despite the FTSE 100 and the S&P 500 hitting record highs, Stephen Wright’s list of shares to buy in August…

Read more »